- Medical technology company RxSight ( NASDAQ: RXST ) expects Q4 revenue of ~$16.1M, representing growth of around 91% Y/Y. Analysts expect the company to generate $14.63M revenue for the quarter .
- The quarterly revenue growth was driven by the sale of 57 Light Delivery Devices (LDDs) and 9,123 Light Adjustable Lenses (LALs).
- Full year 2022 revenue is expected to be ~$49M (+117% Y/Y) vs. $47.53M consensus. The company sold 195 LDDs and 25,284 LALs during the year.
- Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2022, is expected to be $105.8M.
- Audited full-year 2022 and unaudited fourth quarter 2022 financial results are anticipated to be announced in early March 2023.
For further details see:
RxSight guides Q4 revenue growth of 91% Y/Y